{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:33:48Z","timestamp":1789612428779,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canlet.2021.09.028","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T23:33:31Z","timestamp":1632353611000},"page":"184-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine"],"prefix":"10.1016","volume":"522","author":[{"given":"Wei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuandong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4054-9367","authenticated-orcid":false,"given":"Siliang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Ping (Gordon)","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-2077","authenticated-orcid":false,"given":"Xiaoling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.09.028_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/imt-2016-0112","article-title":"Adoptive cell therapy: past, present and future","volume":"9","author":"Cohen","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2021.09.028_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41423-020-0468-x","article-title":"Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient","volume":"17","author":"Abd Hamid","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.coi.2010.01.020","article-title":"Adoptive T cell therapy of cancer","volume":"22","author":"Brenner","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nprot.2017.130","article-title":"Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents","volume":"13","author":"Obermajer","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2021.09.028_bib5","doi-asserted-by":"crossref","first-page":"108609","DOI":"10.1016\/j.celrep.2020.108609","article-title":"Mechanical stiffness controls dendritic cell metabolism and function","volume":"34","author":"Chakraborty","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.09.028_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cellimm.2017.01.011","article-title":"Dendritic cells that highly express SOCS1 induce T-cell hypo-responsiveness and prolong islet allograft survival","volume":"314","author":"Lu","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2017.07.003","article-title":"Cancer immunotherapy: moving forward with peptide T cell vaccines","volume":"47","author":"Kumai","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2016.01.021","article-title":"Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses","volume":"374","author":"Dashti","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2021.09.028_bib9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/imt.15.73","article-title":"The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies","volume":"7","author":"Kajihara","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2021.09.028_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00262-013-1510-y","article-title":"Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model","volume":"63","author":"Bauer","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2021.09.028_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2021.09.028_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.it.2017.07.007","article-title":"Dendritic cells as inducers of peripheral tolerance","volume":"38","author":"Iberg","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2021.09.028_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-017-0455-6","article-title":"Blocking the PD-1\/PD-L1 pathway in glioma: a potential new treatment strategy","volume":"10","author":"Xue","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2021.09.028_bib15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2021.09.028_bib16","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma","volume":"23","author":"Barone","year":"2017","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.028_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017750121","article-title":"Evaluation of PD-L1\/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer","volume":"10","author":"Kallergi","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.canlet.2021.09.028_bib18","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.028_bib19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14712598.2017.1339030","article-title":"Future perspectives for personalized immunotherapy in renal cell carcinoma","volume":"17","author":"Ciccarese","year":"2017","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.canlet.2021.09.028_bib20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.canlet.2021.09.028_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/0008-5472.CAN-17-0491","article-title":"Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy","volume":"78","author":"Taylor","year":"2018","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.028_bib22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1200\/JCO.2016.67.5140","article-title":"Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry","volume":"35","author":"Liang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.09.028_bib23","first-page":"36","article-title":"China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy","volume":"39","author":"Zhou","year":"2019","journal-title":"Canc. Commun."},{"key":"10.1016\/j.canlet.2021.09.028_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","article-title":"Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China","volume":"154","author":"Xu","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.canlet.2021.09.028_bib25","article-title":"Importance of human papillomavirus infection in squamous cell carcinomas of the tongue in Guangdong Province, China","volume":"48","author":"Huang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.canlet.2021.09.028_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/joim.13010","article-title":"A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine","volume":"287","author":"N\u00e4sman","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.canlet.2021.09.028_bib27","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.2147\/IJN.S107194","article-title":"Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications","volume":"11","author":"Wang","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2021.09.028_bib28","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.2147\/IJN.S39428","article-title":"Nanobodies as novel agents for disease diagnosis and therapy","volume":"8","author":"Siontorou","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2021.09.028_bib29","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib30","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/anie.201708459","article-title":"Nanobodies: chemical functionalization strategies and intracellular applications","volume":"57","author":"Schumacher","year":"2018","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.canlet.2021.09.028_bib31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1361094","article-title":"Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells","volume":"6","author":"He","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.09.028_bib33","first-page":"2091","article-title":"Dendritic cells based immunotherapy","volume":"7","author":"Shang","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.canlet.2021.09.028_bib34","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.4049\/jimmunol.1002845","article-title":"TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection","volume":"186","author":"Jelinek","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.09.028_bib36","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1166\/jbn.2018.2616","article-title":"Fusion of dendritic cells and cancer-associated fibroblasts for activation of anti-tumor cytotoxic T lymphocytes","volume":"14","author":"Qian","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.canlet.2021.09.028_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00262-002-0284-4","article-title":"Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination","volume":"51","author":"Galea-Lauri","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2021.09.028_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060828","article-title":"Dendritic-tumor fusion cell-based cancer vaccines","volume":"17","author":"Koido","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.09.028_bib39","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.4049\/jimmunol.179.7.4874","article-title":"Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells","volume":"179","author":"Koido","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib40","article-title":"A potential antitumor effect of dendritic cells fused with cancer stem cells in hepatocellular carcinoma","volume":"2019","author":"Pang","year":"2019","journal-title":"Stem Cell. Int."},{"key":"10.1016\/j.canlet.2021.09.028_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1574887115666200622161418","article-title":"Management of immunotherapy adverse events in oncological patients: anti-CTLA-4, anti-PD-1\/PD-L1","volume":"15","author":"Brigida","year":"2020","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.canlet.2021.09.028_bib42","doi-asserted-by":"crossref","first-page":"6984948","DOI":"10.1155\/2018\/6984948","article-title":"Anti-PD-1\/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies","volume":"2018","author":"Sui","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.canlet.2021.09.028_bib43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2021.09.028_bib45","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/1078-0432.CCR-13-2234","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin. Canc. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:59:55Z","timestamp":1759593595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521004882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"alternative-id":["S0304383521004882"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.028","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}